A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence

NCT06851104 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

45

Enrollment

OTHER

Sponsor class

Stopped The support from the relevant company was not obtained as planned

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Cadonilimab (AK104)

Sponsor

Guangxi Medical University